

## 7 Literaturverzeichnis

1. **Samols E, Bonner-Weir S, Weir GC** 1986 Intra-islet insulin-glucagon-somatostatin relationships. *Clin Endocrinol Metab* 15:33-58
2. **Weir GC, Bonner-Weir S** 1990 Islets of Langerhans: the puzzle of intraislet interactions and their relevance to diabetes. *J Clin Invest* 85:983-987
3. **Bonner-Weir S, Weir GC** 1979 The organization of the endocrine pancreas: a hypothetical unifying view of the phylogenetic differences. *Gen Comp Endocrinol* 38:28-37
4. **Taha C, Klip A** 1999 The insulin signaling pathway. *J Membr Biol* 169:1-12
5. **Bruning JC, Gautam D, Burks DJ, Gillette J, Schubert M, Orban PC, Klein R, Krone W, Muller-Wieland D, Kahn CR** 2000 Role of brain insulin receptor in control of body weight and reproduction. *Science* 289:2122-2125
6. **Obici S, Zhang BB, Karkanias G, Rossetti L** 2002 Hypothalamic insulin signaling is required for inhibition of glucose production. *Nat Med* 8:1376-1382
7. **Jiang G, Zhang BB** 2003 Glucagon and regulation of glucose metabolism. *Am J Physiol Endocrinol Metab* 284:E671-E678
8. **Stevenson RW, Williams PE, Cherrington AD** 1987 Role of glucagon suppression on gluconeogenesis during insulin treatment of the conscious diabetic dog. *Diabetologia* 30:782-790
9. **Jelinek LJ, Lok S, Rosenberg GB, Smith RA, Grant FJ, Biggs S, Bensch PA, Kuijper JL, Sheppard PO, Sprecher CA, .** 1993 Expression cloning and signaling properties of the rat glucagon receptor. *Science* 259:1614-1616
10. **Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R** 1973 Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. *Science* 179:77-79
11. **Weir GC, Schwarz JA, Mathe CJ** 1980 Inhibition of glucagon and insulin secretion from the perfused rat pancreas by a B-cell-selective somatostatin analog. *Metabolism* 29:68-70
12. **Weir GC, Bonner-Weir S** 1985 Pancreatic somatostatin. *Adv Exp Med Biol* 188:403-423

13. **Patel YC** 1999 Somatostatin and its receptor family. *Front Neuroendocrinol* 20:157-198
14. **Patel YC** 1997 Molecular pharmacology of somatostatin receptor subtypes. *J Endocrinol Invest* 20:348-367
15. **Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Niznik H, Srikant CB** 1995 The somatostatin receptor family. *Life Sci* 57:1249-1265
16. **Hunyady B, Hipkin RW, Schonbrunn A, Mezey E** 1997 Immunohistochemical localization of somatostatin receptor SST2A in the rat pancreas. *Endocrinology* 138:2632-2635
17. **Mitra SW, Mezey E, Hunyady B, Chamberlain L, Hayes E, Foor F, Wang Y, Schonbrunn A, Schaeffer JM** 1999 Colocalization of somatostatin receptor sst5 and insulin in rat pancreatic beta-cells. *Endocrinology* 140:3790-3796
18. **Kahn CR** 1994 Banting Lecture. Insulin action, diabetogenes, and the cause of type II diabetes. *Diabetes* 43:1066-1084
19. **DeFronzo RA** 1988 Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. *Diabetes* 37:667-687
20. **Weyer C, Bogardus C, Mott DM, Pratley RE** 1999 The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. *J Clin Invest* 104:787-794
21. **D'Alessandris C, Andreozzi F, Federici M, Cardellini M, Brunetti A, Ranalli M, Del Guerra S, Lauro D, Del Prato S, Marchetti P, Lauro R, Sesti G** 2004 Increased O-glycosylation of insulin signaling proteins results in their impaired activation and enhanced susceptibility to apoptosis in pancreatic beta-cells. *FASEB J* 18:959-961
22. **Unger RH, Orci L** 1975 The essential role of glucagon in the pathogenesis of diabetes mellitus. *Lancet* 1:14-16
23. **Unger RH** 1976 The Banting Memorial Lecture 1975. Diabetes and the alpha cell. *Diabetes* 25:136-151
24. **Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA** 2000 Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. *J Clin Endocrinol Metab* 85:4053-4059
25. **Baron AD, Schaeffer L, Shragg P, Kolterman OG** 1987 Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. *Diabetes* 36:274-283
26. **Butler PC, Rizza RA** 1991 Contribution to postprandial hyperglycemia and effect on initial splanchnic glucose clearance of hepatic glucose cycling in glucose-intolerant or NIDDM patients. *Diabetes* 40:73-81

27. **D'Alessio DA, Ensink JW** 1990 Fasting and postprandial concentrations of somatostatin-28 and somatostatin-14 in type II diabetes in men. *Diabetes* 39:1198-1202
28. **Segers O, De Vroede M, Michotte Y, Somers G** 1989 Basal and tolbutamide-induced plasma somatostatin in healthy subjects and in patients with diabetes and impaired glucose tolerance. *Diabet Med* 6:232-238
29. **Candrina R, Giustina G** 1988 Effect of a new long-acting somatostatin analogue (SMS 201-995) on glycemic and hormonal profiles in insulin-treated type II diabetic patients. *J Endocrinol Invest* 11:501-507
30. **Clissold SP, Edwards C** 1988 Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. *Drugs* 35:214-243
31. **Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM** 2000 Metformin reverses fatty liver disease in obese, leptin-deficient mice. *Nat Med* 6:998-1003
32. **Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE** 2001 Role of AMP-activated protein kinase in mechanism of metformin action. *J Clin Invest* 108:1167-1174
33. **Sinha A, Formica C, Tsalamandris C, Panagiotopoulos S, Hendrich E, DeLuise M, Seeman E, Jerums G** 1996 Effects of insulin on body composition in patients with insulin-dependent and non-insulin-dependent diabetes. *Diabet Med* 13:40-46
34. **Rigalleau V, Delafaye C, Baillet L, Vergnot V, Brunou P, Gatta B, Gin H** 1999 Composition of insulin-induced body weight gain in diabetic patients: a bio-impedance study. *Diabetes Metab* 25:321-328
35. **Torbay N, Bracco EF, Geliebter A, Stewart IM, Hashim SA** 1985 Insulin increases body fat despite control of food intake and physical activity. *Am J Physiol* 248:R120-R124
36. **Henricsson M, Janzon L, Groop L** 1995 Progression of retinopathy after change of treatment from oral antihyperglycemic agents to insulin in patients with NIDDM. *Diabetes Care* 18:1571-1576
37. **Rendell M** 2004 The role of sulphonylureas in the management of type 2 diabetes mellitus. *Drugs* 64:1339-1358
38. **Efanova IB, Zaitsev SV, Zhivotovsky B, Kohler M, Efendic S, Orrenius S, Berggren PO** 1998 Glucose and tolbutamide induce apoptosis in pancreatic beta-cells. A process dependent on intracellular Ca<sup>2+</sup> concentration. *J Biol Chem* 273:33501-33507

39. **Iwakura T, Fujimoto S, Kagimoto S, Inada A, Kubota A, Someya Y, Ihara Y, Yamada Y, Seino Y** 2000 Sustained enhancement of Ca(2+) influx by glibenclamide induces apoptosis in RINm5F cells. *Biochem Biophys Res Commun* 271:422-428
40. **Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY** 2005 Sulfonylurea induced beta-cell apoptosis in cultured human islets. *J Clin Endocrinol Metab* 90:501-506
41. **Willson TM, Lambert MH, Kliewer SA** 2001 Peroxisome proliferator-activated receptor gamma and metabolic disease. *Annu Rev Biochem* 70:341-367
42. **Woods SC, Lotter EC, McKay LD, Porte D, Jr.** 1979 Chronic intracerebroventricular infusion of insulin reduces food intake and body weight of baboons. *Nature* 282:503-505
43. **Zhang B, Salituro G, Szalkowski D, Li Z, Zhang Y, Royo I, Vilella D, Diez MT, Pelaez F, Ruby C, Kendall RL, Mao X, Griffin P, Calaycay J, Zierath JR, Heck JV, Smith RG, Moller DE** 1999 Discovery of a small molecule insulin mimetic with antidiabetic activity in mice. *Science* 284:974-977
44. **Brand CL, Rolin B, Jorgensen PN, Svendsen I, Kristensen JS, Holst JJ** 1994 Immunoneutralization of endogenous glucagon with monoclonal glucagon antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats. *Diabetologia* 37:985-993
45. **Liang Y, Osborne MC, Monia BP, Bhanot S, Gaarde WA, Reed C, She P, Jetton TL, Demarest KT** 2004 Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. *Diabetes* 53:410-417
46. **Van Tine BA, Azizeh BY, Trivedi D, Phelps JR, Houslay MD, Johnson DG, Hruby VJ** 1996 Low level cyclic adenosine 3',5'-monophosphate accumulation analysis of [des-His1, des- Phe6, Glu9] glucagon-NH2 identifies glucagon antagonists from weak partial agonists/antagonists. *Endocrinology* 137:3316-3322
47. **Unson CG, Gurzenda EM, Merrifield RB** 1989 Biological activities of des-His1[Glu9]glucagon amide, a glucagon antagonist. *Peptides* 10:1171-1177
48. **Johnson DG, Goebel CU, Hruby VJ, Bregman MD, Trivedi D** 1982 Hyperglycemia of diabetic rats decreased by a glucagon receptor antagonist. *Science* 215:1115-1116
49. **Cascieri MA, Koch GE, Ber E, Sadowski SJ, Louzides D, de Laszlo SE, Hacker C, Hagmann WK, MacCoss M, Chicchi GG, Vicario PP** 1999 Characterization of a novel, non-peptidyl antagonist of the human glucagon receptor. *J Biol Chem* 274:8694-8697
50. **Chang LL, Sidler KL, Cascieri MA, de Laszlo S, Koch G, Li B, MacCoss M, Mantlo N, O'Keefe S, Pang M, Rolando A, Hagmann WK** 2001 Substituted

- imidazoles as glucagon receptor antagonists. *Bioorg Med Chem Lett* 11:2549-2553
51. **de Laszlo SE, Hacker C, Li B, Kim D, MacCoss M, Mantlo N, Pivnichny JV, Colwell L, Koch GE, Cascieri MA, Hagmann WK** 1999 Potent, orally absorbed glucagon receptor antagonists. *Bioorg Med Chem Lett* 9:641-646
  52. **Madsen P, Ling A, Plewe M, Sams CK, Knudsen LB, Sidelmann UG, Ynddal L, Brand CL, Andersen B, Murphy D, Teng M, Truesdale L, Kiel D, May J, Kuki A, Shi S, Johnson MD, Teston KA, Feng J, Lakis J, Anderes K, Gregor V, Lau J** 2002 Optimization of alkylidene hydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6-tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide. *J Med Chem* 45:5755-5775
  53. **Ling A, Plewe M, Gonzalez J, Madsen P, Sams CK, Lau J, Gregor V, Murphy D, Teston K, Kuki A, Shi S, Truesdale L, Kiel D, May J, Lakis J, Anderes K, Iatsimirskaia E, Sidelmann UG, Knudsen LB, Brand CL, Polinsky A** 2002 Human glucagon receptor antagonists based on alkylidene hydrazides. *Bioorg Med Chem Lett* 12:663-666
  54. **Ling A, Hong Y, Gonzalez J, Gregor V, Polinsky A, Kuki A, Shi S, Teston K, Murphy D, Porter J, Kiel D, Lakis J, Anderes K, May J, Knudsen LB, Lau J** 2001 Identification of alkylidene hydrazides as glucagon receptor antagonists. *J Med Chem* 44:3141-3149
  55. **Petersen KF, Sullivan JT** 2001 Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. *Diabetologia* 44:2018-2024
  56. **Berk SC, Rohrer SP, Degrado SJ, Birzin ET, Mosley RT, Hutchins SM, Pasternak A, Schaeffer JM, Underwood DJ, Chapman KT** 1999 A combinatorial approach toward the discovery of non-peptide, subtype-selective somatostatin receptor ligands. *J Comb Chem* 1:388-396
  57. **Rohrer SP, Birzin ET, Mosley RT, Berk SC, Hutchins SM, Shen DM, Xiong Y, Hayes EC, Parmar RM, Foor F, Mitra SW, Degrado SJ, Shu M, Klopp JM, Cai SJ, Blake A, Chan WW, Pasternak A, Yang L, Patchett AA, Smith RG, Chapman KT, Schaeffer JM** 1998 Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. *Science* 282:737-740
  58. **Rohrer SP, Schaeffer JM** 2000 Identification and characterization of subtype selective somatostatin receptor agonists. *J Physiol Paris* 94:211-215
  59. **Yang L, Berk SC, Rohrer SP, Mosley RT, Guo L, Underwood DJ, Arison BH, Birzin ET, Hayes EC, Mitra SW, Parmar RM, Cheng K, Wu TJ, Butler BS, Foor F, Pasternak A, Pan Y, Silva M, Freidinger RM, Smith RG, Chapman K, Schaeffer JM, Patchett AA** 1998 Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2. *Proc Natl Acad Sci U S A* 95:10836-10841

60. **Strowski MZ, Kohler M, Chen HY, Trumbauer ME, Li Z, Szalkowski D, Gopal-Truter S, Fisher JK, Schaeffer JM, Blake AD, Zhang BB, Wilkinson HA** 2003 Somatostatin receptor subtype 5 regulates insulin secretion and glucose homeostasis. *Mol Endocrinol* 17:93-106
61. **Zheng H, Bailey A, Jiang MH, Honda K, Chen HY, Trumbauer ME, Van der Ploeg LH, Schaeffer JM, Leng G, Smith RG** 1997 Somatostatin receptor subtype 2 knockout mice are refractory to growth hormone-negative feedback on arcuate neurons. *Mol Endocrinol* 11:1709-1717
62. **Air EL, Strowski MZ, Benoit SC, Conarello SL, Salituro GM, Guan XM, Liu K, Woods SC, Zhang BB** 2002 Small molecule insulin mimetics reduce food intake and body weight and prevent development of obesity. *Nat Med* 8:179-183
63. **Strowski MZ, Li Z, Szalkowski D, Shen X, Guan XM, Juttner S, Moller DE, Zhang BB** 2004 Small-molecule insulin mimetic reduces hyperglycemia and obesity in a nongenetic mouse model of type 2 diabetes. *Endocrinology* 145:5259-5268
64. **Dallas-Yang Q, Shen X, Strowski M, Brady E, Saperstein R, Gibson RE, Szalkowski D, Qureshi SA, Candelore MR, Fenyk-Melody JE, Parmee ER, Zhang BB, Jiang G** 2004 Hepatic glucagon receptor binding and glucose-lowering in vivo by peptidyl and non-peptidyl glucagon receptor antagonists. *Eur J Pharmacol* 501:225-234
65. **Shiao LL, Cascieri MA, Trumbauer M, Chen H, Sullivan KA** 1999 Generation of mice expressing the human glucagon receptor with a direct replacement vector. *Transgenic Res* 8:295-302
66. **Christophe J** 1996 Glucagon and its receptor in various tissues. *Ann N Y Acad Sci* 805:31-42
67. **Burcelin R, Katz EB, Charron MJ** 1996 Molecular and cellular aspects of the glucagon receptor: role in diabetes and metabolism. *Diabetes Metab* 22:373-396
68. **Strowski MZ, Parmar RM, Blake AD, Schaeffer JM** 2000 Somatostatin inhibits insulin and glucagon secretion via two receptors subtypes: an in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice. *Endocrinology* 141:111-117
69. **Blake AD, Badway AC, Strowski MZ** 2004 Delineating somatostatin's neuronal actions. *Curr Drug Targets CNS Neurol Disord* 3:153-160
70. **Strowski MZ, Dashkevicz MP, Parmar RM, Wilkinson H, Kohler M, Schaeffer JM, Blake AD** 2002 Somatostatin receptor subtypes 2 and 5 inhibit corticotropin-releasing hormone-stimulated adrenocorticotropin secretion from AtT-20 cells. *Neuroendocrinology* 75:339-346
71. **Obici S, Feng Z, Karkanias G, Baskin DG, Rossetti L** 2002 Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats. *Nat Neurosci* 5:566-572

72. **Schwartz MW, Figlewicz DP, Baskin DG, Woods SC, Porte D, Jr.** 1992 Insulin in the brain: a hormonal regulator of energy balance. *Endocr Rev* 13:387-414
73. **Cone RD, Cowley MA, Butler AA, Fan W, Marks DL, Low MJ** 2001 The arcuate nucleus as a conduit for diverse signals relevant to energy homeostasis. *Int J Obes Relat Metab Disord* 25 Suppl 5:S63-S67
74. **Hallschmid M, Benedict C, Schultes B, Fehm HL, Born J, Kern W** 2004 Intranasal insulin reduces body fat in men but not in women. *Diabetes* 53:3024-3029
75. **Hallschmid M, Benedict C, Born J, Fehm HL, Kern W** 2004 Manipulating central nervous mechanisms of food intake and body weight regulation by intranasal administration of neuropeptides in man. *Physiol Behav* 83:55-64
76. **Chavin KD, Yang S, Lin HZ, Chatham J, Chacko VP, Hoek JB, Walajtys-Rode E, Rashid A, Chen CH, Huang CC, Wu TC, Lane MD, Diehl AM** 1999 Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. *J Biol Chem* 274:5692-5700
77. **Shimomura I, Bashmakov Y, Horton JD** 1999 Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. *J Biol Chem* 274:30028-30032
78. **Gelling RW, Du XQ, Dichmann DS, Romer J, Huang H, Cui L, Obici S, Tang B, Holst JJ, Fledelius C, Johansen PB, Rossetti L, Jelicks LA, Serup P, Nishimura E, Charron MJ** 2003 Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. *Proc Natl Acad Sci U S A* 100:1438-1443
79. **Qureshi SA, Rios CM, Xie D, Yang X, Tota LM, Ding VD, Li Z, Bansal A, Miller C, Cohen SM, Jiang G, Brady E, Saperstein R, Duffy JL, Tata JR, Chapman KT, Moller DE, Zhang BB** 2004 A novel glucagon receptor antagonist inhibits glucagon-mediated biological effects. *Diabetes* 53:3267-3273
80. **Lunetta M, Di Mauro M, Le Moli R, Nicoletti F** 1997 Effects of octreotide on glycaemic control, glucose disposal, hepatic glucose production and counterregulatory hormones secretion in type 1 and type 2 insulin treated diabetic patients. *Diabetes Res Clin Pract* 38:81-89